The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Real-world experience of cancer patients with clonal hematopoiesis in an urban county hospital system.
 
Isabela Bumanlag
No Relationships to Disclose
 
Victoria Chu
No Relationships to Disclose
 
Chijioke Nze
No Relationships to Disclose
 
Hilary Ma
No Relationships to Disclose
 
Guillermo Garcia-Manero
Honoraria - Ascentage Pharma; Bristol-Myers Squibb/Celgene; Curis; Keros Therapeutics
Consulting or Advisory Role - Ascentage Pharma; Bristol-Myers Squibb; Curis; Keros Therapeutics; SERVIER; Taiho Oncology; Takeda
Research Funding - Abbvie; Ascentage Pharma; AstraZeneca; Bristol-Myers Squibb; Chordia Therapeutics; Curis; Genentech; GlaxoSmithKline; Novartis; Rigel; SERVIER; Taiho Oncology; Takeda; Zentalis
 
Christopher Flowers
Stock and Other Ownership Interests - Foresight Diagnostics; N Power
Consulting or Advisory Role - AstraZeneca; BeiGene; Bristol-Myers Squibb/Celgene; Curio Science; Denovo Biopharma; Epizyme; Foresight Diagnostics; Genentech/Roche; Genmab; Gilead Sciences; MorphoSys; Pharmacyclics/Janssen
Research Funding - 4D Pharma (Inst); Abbvie (Inst); Acerta Pharma (Inst); Adaptimmune (Inst); Alimera Sciences (Inst); Amgen (Inst); Bayer (Inst); Celgene (Inst); Cellectis (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Guardant Health (Inst); Iovance Biotherapeutics (Inst); Janssen Oncology (Inst); Kite/Gilead (Inst); Millennium (Inst); MorphoSys (Inst); Nektar (Inst); Novartis (Inst); Pfizer (Inst); Pharmacyclics (Inst); Sanofi (Inst); Takeda (Inst); TG Therapeutics (Inst); Xencor (Inst); ZIOPHARM Oncology (Inst)
 
Kelly Chien
No Relationships to Disclose